구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Capecitabine tablets (Capecitabine tablets) RemeGen Co., Ltd.·Recurrent or Metastatic Nasopharyn… 90 trials |
|---|---|
Overview Program | Capecitabine tablets |
Overview Company | RemeGen Co., Ltd. |
Overview Modality | ADC |
Overview Target | Recurrent or Metastatic Nasopharyngeal C |
Overview Indication | Breast Cancer |
Overview Phase | PHASE_3 |
Overview Status | ACTIVE |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Linker | linkers; loading and releasing rates of the drug were investigated using the proposed |
MoA Biomarker | HER2-Positive |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse, In vitro |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse, In vitro |
Toxicology Major finding | Cardiac Arrest Due to Capecitabine Toxicosis Treated With ECMO and CRRT: A Case Report.. This is the first report of a patient who developed cardiogenic shock after receiving oral chemotherapy with capecitabine and was treated with venoarterial extracorporeal membrane oxygenation combined with continuous renal replacement therapy. A 58-year-old man developed an arrhythmia that rapidly progressed t… |
Clinical Safety signal | Cardiac Arrest Due to Capecitabine Toxicosis Treated With ECMO and CRRT: A Case Report.. This is the first report of a patient who developed cardiogenic shock after receiving oral chemotherapy with capecitabine and was treated with venoarterial extracorporeal membrane oxygenation combined with continuous renal replacement therapy. A 58-year-old man developed an arrhythmia that rapidly progressed t… |
Clinical Selected reported efficacy | ORR 48.6% |
Clinical Reported ORR | 48.6% |
Clinical Reported PFS | 6.9 |
Clinical Reported OS | 12.5 |
Clinical Result source | ClinicalTrials.gov NCT02494583 |
Clinical Program phase | PHASE_3 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT02494583 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Capecitabine tablets (Capecitabine tablets) RemeGen Co., Ltd.·Recurrent or Metastatic Nasopharyn… 90 trials |
|---|---|
Overview Program | Capecitabine tablets |
Overview Company | RemeGen Co., Ltd. |
Overview Modality | ADC |
Overview Target | Recurrent or Metastatic Nasopharyngeal C |
Overview Indication | Breast Cancer |
Overview Phase | PHASE_3 |
Overview Status | ACTIVE |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Linker | linkers; loading and releasing rates of the drug were investigated using the proposed |
MoA Biomarker | HER2-Positive |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse, In vitro |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse, In vitro |
Toxicology Major finding | Cardiac Arrest Due to Capecitabine Toxicosis Treated With ECMO and CRRT: A Case Report.. This is the first report of a patient who developed cardiogenic shock after receiving oral chemotherapy with capecitabine and was treated with venoarterial extracorporeal membrane oxygenation combined with continuous renal replacement therapy. A 58-year-old man developed an arrhythmia that rapidly progressed t… |
Clinical Safety signal | Cardiac Arrest Due to Capecitabine Toxicosis Treated With ECMO and CRRT: A Case Report.. This is the first report of a patient who developed cardiogenic shock after receiving oral chemotherapy with capecitabine and was treated with venoarterial extracorporeal membrane oxygenation combined with continuous renal replacement therapy. A 58-year-old man developed an arrhythmia that rapidly progressed t… |
Clinical Selected reported efficacy | ORR 48.6% |
Clinical Reported ORR | 48.6% |
Clinical Reported PFS | 6.9 |
Clinical Reported OS | 12.5 |
Clinical Result source | ClinicalTrials.gov NCT02494583 |
Clinical Program phase | PHASE_3 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT02494583 |
추천 비교
추천 비교